Arca
Skip to content
Tools
Tools

Meningitis

Drug research and approvals for meningitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 41 studies of meningitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 2 approved and 3 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 41
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 2
  • EU medicines: 5

Recruiting now

Newest posted first, of 41 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 7

Phase 3 5

Phase 2 4

Phase 1 or earlier 2

How its trials ended

384 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 116 whose ending is known, 65% met their primary endpoint, 8% missed it and 28% stopped early.

  • Completed, result not reported16944%
  • Met its primary endpoint7520%
  • Status unknown5715%
  • Ongoing4211%
  • Stopped: other or unclear164%
  • Stopped: enrollment or feasibility123%
  • Missed its primary endpoint92%
  • Stopped: sponsor or business decision41%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 15, 2022"a phase 1/2, multicenter, randomized, active-controlled, observer-blind, age de-escalation study to evaluate the safety, tolerability, and immunogenicity of…Pneumococcal 25-VALENT conjugate vaccine (ivt PCV-25)Inventprise Inc.Pending
Nov 13, 2020A phase IIIb, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of gsk's meningococcal abcwy vaccine when administered in…Combined meningococcal groups a, b, c, w and y vaccine (GSK3536819A)GSKOngoing
Aug 20, 2020A phase III, randomized, controlled, observer-blind study to domonstrate effectiveness, immunogenicity and safety of gsk's meningococcal group b and combined…GSK3536819A (combined meningococcal groups a, b, c, w and y vaccine)GSKOngoing
Jun 14, 2018A phase 2b, randomized, controlled, observer-blind, multi-center, non-inferiority immunogenicity and safety study of two formulations of gsk biologicals…Meningococcal (serogroups a, c, w and y) oligosaccharide CRM197 conjugate…GSKOngoing
Sep 17, 2015A phase 3b, open label, controlled, multi center, extension study to assess the persistence of bactericidal activity at 4 to 7.5 years after two dose primary…BexseroNovartis PharmaceuticalsOngoing
Sep 16, 2015Preparedness for and response to meningococcal outbreaks: a pilot study of the immunogenicity, reactogenicity and tolerability of two schedules of a 4cmenb…Bexsero (multicomponent meningococcal b vaccine (recombinant, adsorbed)Dalhousie UniversityPending
Jul 31, 2013"immunogenicity and safety study of 1 and 2 doses of gsk biologicals' meningococcal vaccine GSK134612 in toddlers, persistance up to 5 years after vaccination…NimenrixGSKOngoing

FDA orphan designations

Approved first, then open designations, newest first
Apr 1, 1999DepoCytIntrathecal treatment of lymphomatous meningitis.Pacira Pharmaceuticals, Inc.Approved
Aug 11, 1997AmBisomeTreatment of disseminated cryptococcosis including meningitis.Fujisawa USA, Inc.Approved
Jun 21, 2023Flucytosine Injection for intravenous InfusionTreatment of cryptococcal meningitisCipla Ltd.Designated
Jan 21, 2003MafosfamideTreatment of neoplastic meningitisBaxter Healthcare CorporationDesignated
Mar 5, 2001BusulfanIntrathecal therapy for neoplastic meningitisSuperGen, Inc.Designated

Medicines authorised in the EU

Newest first
Nov 18, 2020MenQuadfiMeningococcal group A, C, W-135 and Y conjugate vaccineSanofi Winthrop IndustrieEMA ↗
May 24, 2017TrumenbaMeningococcal group b vaccine (recombinant, adsorbed)Pfizer Europe MA EEIGEMA ↗
Feb 15, 2016VaxelisDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)MCM Vaccine B.V.EMA ↗
Jan 13, 2013BexseroMeningococcal group B Vaccine (rDNA, component, adsorbed)GSK Vaccines S.r.l.EMA ↗
Apr 20, 2012NimenrixMeningococcal groups A, C, W-135 and Y conjugate vaccinePfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.